{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:10Z","timestamp":1791644770716,"version":"4.3.4"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Dry eye disease (DED) is a prevalent eye disorder. Cyclosporine is an effective immunomodulator that is widely used in DED; however, due to its highly hydrophobic nature, delivery of cyclosporine to the ocular surface is challenging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a multicenter, double-blind, vehicle-controlled, phase 3 randomized clinical trial conducted from March 4, 2021, to July 22, 2022. Adult participants with moderate to severe DED were recruited from 12 hospitals in China. Study data were analyzed April 2, 2022, for the primary analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Following a 14-day run-in period with an artificial tear, participants were randomly assigned (1:1) to receive water-free cyclosporine or vehicle (1 eye drop in each eye twice daily). After a 29-day treatment, participants of both groups were given the option to receive water-free cyclosporine for an additional 12 weeks for longer-term safety assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end points were changes from baseline in total corneal fluorescein staining (tCFS) using the National Eye Institute scale and in dryness score on a visual analog scale at day 29.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 206 participants (mean [SD] age, 47.8 [14.2] years; 185 female [90%]) were enrolled, with 103 each in the cyclosporine group and the vehicle group. At day 29, the cyclosporine group experienced improved tCFS compared with vehicle (change [\u0394]\u2009=\u2009\u22121.8; 95% CI, \u22122.7 to \u22121.0; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), with a tCFS score decrease from baseline of \u22124.8 in the cyclosporine group and \u22123.0 in the vehicle group. Dryness score decreased from baseline in both groups (\u221219.2 vs \u221215.4; \u0394\u2009=\u2009\u22123.8; 95% CI, \u22129.2 to 1.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.17). During the 29-day treatment, treatment-related adverse events were reported in 15 participants (14.6%) in the cyclosporine group and 11 participants (10.7%) in the vehicle group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions And Relevance<\/jats:title><jats:p>Results demonstrated superiority of a water-free cyclosporine, 0.1%, eye solution over vehicle in improving tCFS score at day 29 in Chinese participants with DED. However, dryness score (VAS) was not improved at day 29.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05841043\">NCT05841043<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.0101","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T16:34:02Z","timestamp":1709829242000},"page":"337","source":"Crossref","is-referenced-by-count":30,"title":["Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease"],"prefix":"10.1001","volume":"142","author":[{"given":"Rongmei","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing, China"},{"name":"Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye, Ear, Nose, and Throat, Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Henan Eye Hospital, Henan Provincial People\u2019s Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Zhongshan Ophthalmic Center, Hainan Eye Hospital and Key Laboratory of Ophthalmology, Sun Yat-sen University, Haikou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Gu","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huping","family":"Wu","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center, Department of Ophthalmology, Affiliated to Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Shougang Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxia","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing, China"},{"name":"Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi240006r1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report.","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"eoi240006r2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009729.pub2","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome.","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"11S","key":"eoi240006r3","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.ophtha.2017.08.029","article-title":"Inflammation in dry eye disease: how do we break the cycle?","volume":"124","author":"Rhee","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi240006r4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051.pub2","article-title":"Topical cyclosporine A therapy for dry eye syndrome.","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"31","key":"eoi240006r8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase 3 clinical study.","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"eoi240006r9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease.","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240006r10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease\u2014CsA Phase 3 Study Group.","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi240006r11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial.","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"eoi240006r12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine a solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study.","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"eoi240006r13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts.","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"23","key":"eoi240006r15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMra1407936","article-title":"Dry eye.","volume":"378","author":"Clayton","year":"2018","journal-title":"N Engl J Med"},{"key":"eoi240006r5","unstructured":"U.S. Food and Drug Administration. Restasis prescribing information. Accessed June 6, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/050790lbl.pdf"},{"key":"eoi240006r6","unstructured":"U.S. Food and Drug Administration. Ceque prescrbing information. Accessed June 6, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210913s000lbl.pdf"},{"key":"eoi240006r7","unstructured":"Agency? EM. Ikervis prescrbing information. Accessed September 1, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ikervis"},{"key":"eoi240006r14","unstructured":"O\u2019Rourke? M. Enhancing delivery of topical ocular drops. Accessed September 1, 2023. https:\/\/crstodayeurope.com\/wp-content\/themes\/crste\/assets\/downloads\/0516CRSTEuro_TP_O'Rourke.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2816004\/jamaophthalmology_peng_2024_oi_240006_1712159402.22718.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:02:24Z","timestamp":1713452544000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2816004"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.0101","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}